bdc-1001
bolt biotherapeutics
['bdc-1001']
#boltbio presented comprehensive #clinicaldata at #asco2023 from a phase 1 dose-escalation study of bdc-1001. find detailed data and learn about phase 2 trial plans in the asco poster, now available here: 
Unleashing the power of the immune system to achieve anti-tumor immunity for the nearly 80% of patients who are unresponsive to checkpoint inhibitors.